资源描述：
《维甲酸受体β 在膀胱移行细胞癌中的表达及意义.doc》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。
1、维甲酸受体B在膀胱移行细胞癌中的表达及意义ExpressionofRetinoicAcidReceptorBetainBladderTransitionalCellCarcinomaandItsClinicalSignificance杨金瑞饶建明王龙尹焯刘龙飞何芋YANGJinruiRAOJianmingWANGLongYINZhuoLIULongfeiHEQian中南大学湘雅二医院泌尿外科DepartmentofUrologyoftheSecondXiangyaHospital,CentralSouthUniversity,Changsha,HunanProvince(China
2、410011)中图分类号：737.14文献标识码：A文章编号:1818-0086(2008)02摘要：目的检测维甲酸受体卩(RARP)在膀胱移行细胞癌中的表达，并探讨其意义。方法应用免疫组织化学方法对80例膀胱移行细胞癌组织标本中RARP表达进行检测。男56例,女24例。病理分级I级26例，II级22例，III级32例。临床分期T]20例、丁220例、T322例、TJ8例。复发性膀胱癌46例。10例正常膀胱组织作对照。结果10例正常膀胱黏膜组织中RARP均为强阳性。80例膀胱移行细胞癌中RAR卩阳性表达28例,阳性率为35.0%。RAR卩表达与膀胱移行细胞癌病理分级、临床分期以及复
3、发密切相关(pv0.05X结论RAR[3在膀胱移行细胞癌组织中存在表达缺失,其表达缺失程度与肿瘤病理分级、临床分期及复发相关，可作为观察膀胱移行细胞癌复发指标之一。关键词：膀胱肿瘤；移行细胞癌；维甲酸受体卩AbstractObjectiveTostudytheexpressionofretinoicacidreceptorbeta(RARP)inbladdertransitionalcellcarcinomaanditsclinicalsignificance・MedthodsTheexpressionofRAR卩wasexaminedin80cases(56maleand24fe
4、male)ofthebladdertransitionalcellcarcinomaand10casesofnormalbladdertissue(controls)byimmunohistochemistrymedthod・ThepathologicalgradingshowedGradeIin26cases,GradeIIin22andGradeIIIin32.TheclinicalstagingshowedTiin20cases,T2in20,T3in22andT4in1&Ofthe80cases,46developedrelapse・ResultsTheRARPwasstr
5、onglyexpressedinallthe10casesofnormalbladdertissueswithapositiverateof100%;whereastheoverallpositiverateofRARpinthe80casesofbladdertransitionalcellcarcinomawas35.0%(28/80).ThepositiveratesofRAR卩inGradeI,II,IIIcasesofbladdercarcinomawere76.9%(20/26),22.7%(5/22)and9.4%(3/32)respectively;thediffe
6、rencesofpositiveratesbetweenGradeIandGradeII,GradeIandGradeIIIcaseswassignificant(p<0.05).ThepositiveratesofRARpinThT2>T3andT4casesofbladdertransitionalcellcarcinomawere75.0%(15/20)z45.0%(9/20),13.6%(3/22)and0.06%(1/18),respectively,whichshowedatrendofdecreaseinRARpexpressionfromT
7、toT4stagebla
8、ddertransitionalcellcarcinoma.TherewasstatisticallysignificantdifferencebetweenT]andT3orT4,andbetweenT2andT3orT4stagebladdertransitionalcellcarcinoma(p<0.05).ThepositiverateofRARpincasesofbladdertransitionalcellcarcinomarelapsewas17.4%(
